Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 321331 | [Heterogeneity of antinuclear antibodies (ANA), immunoglobulin- and complement levels in s | 1977 Feb | ANA typing of RA patients according to the heavy- and light chains, complement fixing ability and immunofluorescent staining pattern was performed by the immunofluorescence technique and partially by qualitative immunoelectrophoresis. In the corresponding sera the immunoglobulins and complement components were quantiatively determined. Dependent on the ANA-immunoglobulin classes we found the following distribution: IgG-ANA; 40/93 (43%), IgM-ANA: 19/93 (20%), IgA-ANA: 2/93 (2%), and Ig-comb.-ANA:17/93 (18%). ANA only positive for polyspecific antimmunoglobulin serum: 15/93 (16%). After L-chain typing we found within a given ANA-Ig-class positivity for both L-chain subclasses (kappa and lambda): IgG-ANA: 19/40 (48%), IgM-ANA: 3/19 (16%), IgA-ANA:1/1 and Ig-comb.-ANA: 14/17 (82%). ANA cases within a given Ig-class only positive for the L-chain/type kappa:IgM-ANA:6/19 (32%), IgG-ANA: 9/40 (23%), Ig-comb.-ANA:2/12 (12%). ANA cases within a given Ig-class only positive for the L-chain type lambda: IgM-ANA: 7/19 (37%), IgG-ANA: 3/40 (8%), Ig-comb.-ANA:1/17 (6%) and IgA-ANA:1/1. In all cases of restricted ANA-positivity (only positive by use of polyspecific anti-immunoglobulin serum) no light chains were detected. In total we found approximatively 25% of complement fixing ANA, predominantly IgG-ANA (70%). Concerning the immunofluorescent nuclear staining we stated the following patterns: homogenous: 34/93 (36.6%), speckled: 29/93 (31.2%), mixed pattern : 22/93 (23.6%) peripheral: 5/93 (5.4%) and nucleolar: 3/93 (3.2%). The quantitative Ig-determination reveals a significant increase of IgG in ANA (single type) positive sera. IgG + IGM + IGA-ANA and IgG + IgM-ANA are found together with a significantly increased IgG- and IgM-serum levels, in the case of IgG + IgM-ANA we could demonstrate an additional relative decrease of the complement component C4. Sera with positive complement fixing ANA compared with non complement fixing ANA are characterized by an absolute increase of IgG and relative decrease of the complement component C4. No differences in serum-immunoglobulin- and -complement concentrations were registered dependent on ANA-immunofluorescent staining patterns. | |
| 6252512 | Penicillamine-associated myasthenia gravis. | 1980 Nov | Electroneuromyographic studies have been reported as abnormal in only 9 of 23 cases of penicillamine-associated myasthenia gravis (MG). We report a patient with rheumatoid arthritis who developed clinical and electrodiagnostic evidence of myasthenia 7 months after beginning penicillamine therapy. Six months after discontinuing penicillamine, it was possible to discontinue anticholinesterase medications. With clinical improvement, electrodiagnostic studies (including single-fiber electrmyography) improved, serum antibody titers to human muscle acetylcholine receptor fell, and lymphocytes became more responsive to the nonspecific mitogen phytohemagglutinin. Evidence suggests that penicillamine-associated myasthenia is a distinct syndrome rather than the chance occurrence of two diseases. This syndrome is clinically and electrophysiologically distinguishable from idiopathic myasthenia only by the high remission rate after penicillamine is discontinued. | |
| 6601710 | Peripheral blood T lymphocytes subpopulations in HLA-B7 related rheumatic diseases: ankylo | 1983 Feb | The etiology of B lymphocyte hyperactivity in ankylosing spondylitis (AS) and in reactive synovitis is unknown and data available on the cellular immune system are controversial. We therefore evaluated peripheral blood T cell populations in AS patients and patients with reactive synovitis (RS) using monoclonal antibodies, previously shown to react with all T cells (OKT3), the inducer-helper T cell subset (OKT4) and the suppressor-cytotoxic T cell subset (OKT8). Results were compared with a normal control group and a group of rheumatoid arthritis (RA) patients. In AS an increase of OKT4+ cells was found, but the total number of T helper-inducer cells in peripheral blood was not different from the normal group and the group of patients with RS. Contrary to the results found in RA, where the helper-inducer/suppressor-cytotoxic ratio (OKT4+/OKT8+) was significantly increased, the immunoregulatory ratio in AS and in RS was normal suggesting another mechanism leading to B cell hyperactivity than in RA. | |
| 7054235 | Immunoglobulin G3 subclass production by rheumatoid synovial tissue cultures. | 1982 Jan | The cellular infiltrate in the deeper layers of the rheumatoid synovium produces a substantial amount of immunoglobulin (Ig)G. Culture supernatants of synovial tissues from 31 patients with rheumatoid arthritis (RA) undergoing joint replacement or synovectomy have been analyzed for the subclass of IgG present. IgG3 was measured by separation with Staphylococcal Protein A chromatography, precipitation with specific anti-IgG3 antibody, and differential separation of IgG3 heavy chains using polyacrylamide gel electrophoresis. IgG from RA synovial cultures contained an average of 41% IgG3 (range, 8-97%) compared with 12% IgG3 (range, 6-17%) in the serum IgG of the same patients. A group of non-RA control lymphoid tissues (four lymph nodes and five tonsils) produced 23% of total IgG as the IgG3 subclass (range, 16-35%). An average of only 9% of the synovial IgG showed aggregation compatible with IgG-rheumatoid factor (IgG-RF). Purified IgG from some of the RA synovial culture supernatants also showed significant restriction when separated by isoelectric focusing. This restriction and the enrichment for the IgG3 subclass in the IgG from RA synovial cultures suggest that either an antigen in the inflamed joint is selectively stimulating an antibody in this subclass, or that significantly differences in the catabolic rate of this subclass are found in cultures of synovial tissue when compared with that occurring in intact patients. | |
| 7113368 | [Arthrodesis of the metatarsophalangeal joint of the big toe - a report on six years' expe | 1982 May | At the orthopedic clinic of Lübeck College of Medicine surgical treatment of disorders of the metatarsophalangeal joint of the big toe has, since 1975, included arthrodesis of this joint using a small bone chip. In the light of experience gathered in 150 arthrodeses performed to date, this paper aims to point out major considerations in surgical technique and postoperative treatment; keeping these in mind should help to prevent unsatisfactory courses and optimize results. | |
| 375851 | How long should long be? Long-term trials in rheumatic diseases. | 1979 Apr | In the interests of the safety of patients it is necessary to collect long-term clinical data. It is often assumed that the longer the trial the better. However, the longer the trial the more scientific compromises are necessary if it is to be carried out in a practical way. Because the therapeutic efficacy of and tolerance to the nonsteroidal anti-inflammatory drug diclofenac was established after 6 months' trial the optimal duration for a comparative long-term trial of this preparation is 6 months. The small amount of information gained from trials of diclofenac longer than this did not justify the reduction in quality of trial design and performance that they required. Thus it would appear that at least for 1 antirheumatic drug the assumption that 'the longer the trial the better' is not true. | |
| 340588 | The reaction of SLE antibodies with native, single stranded RNA: radioassay and binding sp | 1978 Feb | Escherichia coli 3H-tRNA and MS2 phage 125I-RNA were prepared and used in a sensitive nitrocellulose filter assay. Antibodies that bound these RNA ligands occurred in the sera of several patients with SLE, but not in sera of patients with other connective tissue diseases. The antibody populations that bound polyribonucleotides (largely IgG) were distinct from antibody populations that bound polydeoxyribonucleotides. Competition experiments showed that the anti-RNA antibodies preferentially bound native ssRNA as compared with synthetic single and double stranded polyribonucleotides. There was increasing affinity with increasing m.w. of the ssRNA. The anti-tRNA population was of restricted heterogeneity (Sips index 0.83) and bound tRNA with an average association constant (Ko) of 9 x 10(6) l/mole at 4 degrees C. The anti-MS2 RNA population was much more heterogeneous (Sips index 0.67) and bound MS2 RNA with a Ko of about 3 x 10(9) l/mole at 4 degrees C. Whereas NZB/NZW mice spontaneously produce RNA reactive antibodies with conformation specificity for native tRNA, human SLE anti-RNA antibodies appear to have very little of this type of conformation specificity. | |
| 449915 | Immune interferon in the circulation of patients with autoimmune disease. | 1979 Jul 5 | The observation that type II, or immune, interferon could be produced by peripheral-blood leukocytes in vitro on an immune-specific basis suggested that it also might be produced in vivo in various autoimmune disorders. We found immune interferon in the serums of patients with systemic lupus erythematosus, rheumatoid arthritis, scleroderma and Sjögren's syndrome. Among 28 patients with systemic lupus erythematosus, 71 per cent of those with active and 21 per cent of those with inactive disease showed interferon in their serums. Serial serum samples showed a good correlation between interferon titers and disease activity. Moreover, interferon titers correlated positively with antibodies to DNA and negatively with serum levels of the third component of complement. It is possible that the production of interferon may contribute to immunologic aberrations in auto-immune diseases and also protect the already compromised host from viral infections. | |
| 339577 | [Intra-articular therapy of chronic arthritides]. | 1977 Oct 1 | The intraarticular therapy with the aim of the direct influence on the pathologically changed synovial membrane increasingly gains significance. On the basis of own results as well as literary data the present possibilities of the local treatment of chronic arthritides are described. After discussion of the advantages and disadvantages of the individual usable preparations a scheme of therapy elaborated for the use of local therapeutics in chronic synovialitis is described. Exact indications for the use of the intraarticular as well as operative methods for therapy of chronic synovialitis must still be established. | |
| 6236640 | Enumeration of T cell subsets and functional suppressor cell assays in patients with rheum | 1984 May | Seronegative rheumatoid arthritis (RA) patients have increased proportions of OKT-4+ (helper) T cells and diminished proportions of OKT-8+ (suppressor/cytotoxic) T cells in the peripheral blood. This phenomenon corresponds to diminished inhibition of B cell activation by peripheral blood lymphocytes (PBL). Seropositive RA patients show a broad range of OKT-8+ T cell proportions (9%-45%) in the peripheral blood, resulting in a mean level comparable to that in controls. Inhibition of T cell activation by suppressor cells in peripheral blood is greater in this group than in controls. HLA-B27-positive arthritis patients show no significant differences from controls with respect to markers and functional suppressor cell assays. In the synovial fluid of all patients both OKT-8+ T cell proportions and functional suppressor cell activity are greatly increased. | |
| 6333305 | Generation of long-term T-cell lines from synovial fluid. | 1984 Nov | Investigations of human autoimmune diseases have largely involved study of circulating T cells. The development of T-cell cloning technology has made possible the study of the small numbers of T cells found at sites of pathological involvement in autoimmune diseases. In this initial communication, the feasibility of in vitro propagation of synovial fluid T cells from patients with arthritis is demonstrated. The generation of long-term, phenotypic helper/inducer, as well as phenotypic suppressor/cytotoxic, interleukin 2-dependent synovial fluid T-cell lines from patients with arthritis is reported. The ability to generate such synovial fluid T-cell lines should now allow for new investigative approaches to human autoimmune arthritic diseases. | |
| 6681147 | False-positive Waaler-Rose test due to anti-rabbit IgM antibodies in IgA deficiency. | 1983 Oct | The presence of antibodies to rabbit IgM in an IgA deficient patient with degenerative arthropathy is described. The anti-IgM antibodies caused a false-positive Waaler-Rose test. Antibodies to rabbit IgM in titres greater than or equal to 1/8 were found in 20 of 35 IgA deficient individuals. No relationship between the patients' symptoms and the presence of these antibodies could be discerned and their biological significance is unknown. Two of 100 normal blood donors, none of 62 rheumatoid arthritis patients and 9 of 50 systemic lupus erythematosus patients showed anti-rabbit IgM antibodies in titres greater than or equal to 1/8. Unless an IgG fraction of antibodies is used for sensitization of erythrocytes in the Waaler-Rose test, the results may be misleading. | |
| 6251856 | Correlation between anti-RANA and anti-EBNA titers in normal subjects with and without HLA | 1980 Sep | We have determined the relationship of antibody titers to the rheumatoid arthritis nuclear antigen (RANA) and of antibody titers to the Epstein-Barr nuclear antigen (EBNA) to each other and to the DRw4 B cell alloantigen in the sera of 34 normal white adults. By a sensitive indirect immunofluorescence (IF) assay, 76% had RANA antibody, compared to 23% by a micro-immunodiffusion assay. The correlation coefficient for the tube dilution titers of anti-RANA and anti-EBNA was 0.61 (P < 10(-4)). The 14 DRw4-positive subjects and the 20 DRw4-negative subjects did not differ with respect to anti-RANA titers (P = 0.51) or anti-EBNA titers (P = 0.89). We conclude that: 1) most normal adults have RANA antibody by IF; 2) anti-RANA and anti-EBNA titers are closely related; 3) the titers of these antibodies cannot be related to the presence of the DRw4 determinant in normal persons. | |
| 6941676 | Evidence for a steroid receptor in rheumatoid synovial tissue cells. | 1980 | One mechanism by which glucocorticoids could exert their anti-inflammatory action is via rapidly saturable, stereo-specific cytoplasmic protein receptors. This report is of an investigation into such a possibility in synovial cells. Synovium, obtained from knee joints of rheumatoid patients undergoing surgery, was incubated with clostridiopeptidase A and trypsin-EDTA to obtain cell suspensions. These, together with cells obtained from synovial fluid aspirated from patients with rheumatoid arthritis, were identified by electron microscopy. Duplicate samples of these cell suspensions were incubated with increasing concentrations of H3Dexamethasone (1 x 10(-10)M-1 x 10(-9)M) for 30 minutes at 37 degrees C. Analysis of the proportion of steroid bound to whole cells showed evidence for specific, rapidly saturable, receptors in the cells obtained from synovial tissue, but this was not found in synovial fluid cells. Electron micrographs showed that cells obtained from synovial tissue consisted of synovial fibroblast - and macrophage-types, lymphocytes, monocytes and macrophages. Polymorphonuclear leucocytes appeared to be absent. However, in synovial fluid cell type polymorphonuclear leucocytes were the predominant cell type. We concluded from this, that one or more of the cell types present in synovial tissue contain a specific steroid receptor, but that this is lacking in synovial fluid polymorphonuclear leucocytes. | |
| 6968215 | Enhanced in vitro synthesis of IgM rheumatoid factor in rheumatoid arthritis. | 1980 Sep | Peripheral blood mononuclear leukocytes (MNL) from 42 patients with classic/definite seropositive rheumatoid arthritis (RA) and 24 healthy adult controls were tested for their capacity to produce IgM rheumatoid factor (RF) in vitro in the presence and absence of pokeweed mitogen (PWM). In no instance was spontaneous elaboration of IgM RF from control MNL observed. In contrast, MNL from 16 of the 42 RA patients spontaneously synthesized IgM RF (22 +/- 43 ng/culture) which constituted a substantial fraction of the total IgM in these culture fluids (48 +/- 26%). Pokeweed mitogen induced detectable quantities of IgM RF in MNL culture supernatants from 10 of 24 controls (12 +/- 11 ng/culture) and 33 of 42 RA patients (60 +/- 82 ng/culture, P = 0.008). IgM RF constituted a significantly higher proportion of the total IgM in RA MNL supernatants than in control supernatants (11 +/- 11% versus 1.01 +/- 1.03%; P = 0.013). IgM RF production (spontaneous and PWM-induced) was dependent upon de novo protein synthesis. The results indicate that B cells programmed to produce IgM RF are present in both normal and RA B cell repertoires, but are preferentially expressed in RA. | |
| 6124671 | A double-blind placebo-controlled trial of methylprednisolone pulse therapy in active rheu | 1982 Jul 31 | To confirm the findings of uncontrolled trials that methylprednisolone pulse therapy (MPPT) is a safe treatment for active rheumatoid disease, a double-blind trial was conducted in which 20 patients with active rheumatoid disease were randomly allocated to receive an infusion of either 1 g methylprednisolone or placebo. Methylprednisolone produced significant improvement in all clinical variables measured, a benefit which was sustained for at least 6 weeks. The placebo produced only transient improvement in some of the clinical variables measured. when the 10 placebo groups patients were later given an infusion of 1 g methylprednisolone, they too showed significant clinical benefit. The methylprednisolone also gave rise to improvements in some haematological and biochemical variables. | |
| 310087 | [Therapeutic efficacy and tolerance of a new drug, sodium diclofenac, in inflammatory and | 1978 Oct 13 | A new antirheumatic, non-steroid drug, sodium diclofenac (Voltaren Geigy) has been experimented in 14 patients aged between 27 and 69 hospitalized at the IInd Medical Division of Enna Hospital. The patients were divided into three groups suffering from: rheumatoid arthritis, scapulohumeral periarthritis, uratic arthritis, and rheumatic carditis in active phase. In almost all treated cases, the drug proved to have good therapeutic effectiveness demonstrated by complete remission or attenuation of clinical symptomatology and by the return to normal or reduction in the various modified biohumoral indices; in all cases treated, good tolerance, absolute lack of side-effects and toxicity. Special attention has been paid to study of possible changes to gastric mucosa by means of careful evaluation of endoscopic and histological findings. | |
| 6813486 | The problems of studying disease-remittive agents in RA. | 1982 Jul | Problems in trials of disease-remittive agents include the slow action and late side effects of these compounds, the lack of immediate benefit to the patient, their characteristic and sometimes dangerous side effects, variability of response, natural fluctuation of the disease, and uncertain definition of drug types. To overcome these problems, trials must be of long duration with large numbers of patients whose characteristics are clearly defined. The 2/3 blind technique overcomes the problem of side effects. Measurements must include aspects of the disease state as well as its articular manifestations. Criteria for the identification of disease-remittive agents include effects in animal models of inflammation, time course, disease-dependence, effects on joint disease and extraarticular manifestations, changes in erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), and immunoglobulins, radiological progression, outcome, and perhaps side effects. The time course of the action of auranofin (AF), similar to that of Myochrysine, with its effects on ESR and RF, support the view that AF is a disease-remittive agent. | |
| 7084281 | An update on long-term efficacy and safety with benoxaprofen. | 1982 | Studies with benoxaprofen in rheumatoid arthritis and osteoarthritis, conducted in more than 2000 patients, continue to demonstrate its safety and effectiveness. In long-term, double-blind, parallel studies, benoxaprofen administered as a single daily dose was more efficacious than multiple daily doses of aspirin or ibuprofen. Significant clinical improvement was apparent after one week of benoxaprofen therapy in rheumatoid arthritis and osteoarthritis. Additional improvement was noted after 6 and 12 months of therapy. Discontinuation due to lack of efficacy or adverse effects was substantially lower for benoxaprofen than for aspirin or ibuprofen. The erythrocyte sedimentation rate, the rheumatoid factor titer, and alkaline phosphatase were significantly reduced in the benoxaprofen patient group. The incidence of drug-related peptic ulcer disease was 7 in 2204 (0.3%). No other serious gastrointestinal effect was attributable to benoxaprofen. The incidences of drug-related phototoxicity and onycholysis were 9.4 and 12.5%, respectively. These data suggest that benoxaprofen has a superior and perhaps different therapeutic profile than aspirin or ibuprofen. | |
| 6333963 | Determination of complement breakdown fragments C3d and its subfragments in health and dis | 1984 | The breakdown products of the third component of complement in approximately 400 samples were measured by rocket immunoelectrophoresis and two-dimensional electrophoresis using the method of Brandslund et al [3]. It was confirmed that the measurement of the C3d level provides useful information on increased C3 consumption irrespective of the synthetic rate. Furthermore, three subfragments with C3d but without C3c antigenicity were distinguished, which were designated as C3d1, C3d2, and C3d3. The subfragment C3d3 which migrated to the most anodal side was a predominant component in the plasma from patients with autoimmune diseases. Little C3d3 subfragment was detected in normal plasma and in normal sera incubated in vitro for 24 hr. Even in the normal sera converted completely in vitro which contained little intact C3, only a limited amount of C3d3 was detected. In the plasma from postsurgical patients in whom activation of the complement system was considered to be in an acute phase, C3d3 was detected, but the C3d2 level was higher than the C3d3 level. In the plasma from patients with systemic lupus erythematosus having the normal C3d level, C3d3 was a major fragment. It is predicted that the preponderant presence of C3d3 in plasma could be the result of chronic continuous complement activation by immune complexes. |